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1. Introduction 
    The pyrrolobenzodiazepine scaffold 1 (10,11-dihydro-5H-
pyrrolo[2,1-c][1,4]benzodiazepine, Figure 1) is a medicinally 
important heterocycle consisting of a benzo[1,4]diazepine unit 
fused to a pyrrole. This structure is commonly encountered as a 
constituent part of important synthetic drug scaffolds, for 
example, in the development of non-peptidic oxytocin and 
vasopressin small molecule agonists and antagonists, typified by 
Lixivaptan 2 (Figure 1).1    
 
 
 
 
 
 
 
 
Figure 1. The pyrrolobenzodiazepine scaffold 1, Lixivaptan 2 and 
the PDB scaffold 3. 
 
    Also important is the inclusion of the structural template of 1 
within the development of pyrrolo[2,1c][1,4]benzodiazepines 3 
(PBDs) as DNA interactive agents.2   Since their discovery in the 
1960s the field of PBD research has expanded rapidly and now 
includes over thirteen different PBD architectures used across 
synthetic mechanistic and medicinal chemistry and as ‘warheads’ 
in therapeutic antibody applications.3 The utility of 1 requires 
that efficient synthetic methods to access it are available. Several 
chemical syntheses of 1 have been reported in the literature4 and, 
as their key tricycle-forming step, propose a tandem sequence 
involving the reduction of the nitro group in pyrroloaldehyde 4, 
condensation of the resultant aniline moiety with the pyrrolic 
aldehyde and finally reduction of the imine to form 1 (Scheme 1). 
 
 
 
 
 
 
 
 
 
Scheme 1. Access to 1 (via nitro reduction, imine formation and 
reduction) from pyrroloaldehyde 4. 
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    These two transformations are usually completed as a one-
step, domino process where nitro reduction, cyclisation and imine 
reduction are globally effected under hydrogenation conditions.  
    From a process standpoint, the use of gaseous reagents is in 
many ways advantageous. Several equivalents of gas can be used 
to drive reactions to completion and the excess material can 
easily be removed post reaction simply by opening the container. 
However, the use of gasses is often accompanied by significant 
safety issues. As gas concentrations in solution are proportional 
to pressure in the head space (according to Henry's law5), high 
pressures are often required to achieve sufficient concentrations 
for reactions to take place. This generally requires the use of 
specialised high-pressure reactors. As the potential energy stored 
due to pressurisation (which would be converted to kinetic 
energy in the event of a mechanical failure) is proportional to the 
volume of the vessel, this becomes more serious during scale up. 
Hydrogen is also one of the most flammable of gasses and this 
leads to additional fire and explosion hazards.6 Furthermore, as 
interfacial surface-area scales with the square of dimension, 
whilst volume scales with its cube, surface-area to volume ratios 
decrease as the size of the vessel increases (assuming the same 
shape is maintained). This leads to a scale variant rate of gas 
transfer, from the head space into the solution, which often 
becomes rate limiting.  
    In recent years, continuous flow chemistry has emerged as an 
alternative to traditional batch based synthetic protocols.7 Due to 
the fact that only a small amount of material is being processed at 
any one time, through relatively small reaction zones, this can 
often mitigate some of the safety issues associated with the scale-
up of batch reactions, particularly for those transformations that 
involve the formation of hazardous intermediates, or that use 
high temperatures or pressures.8 In addition, as interfacial surface 
contact is often enhanced and well-defined, this can often 
facilitate more efficient and controllable interfacial mass and 
energy transfer.9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cartoon schematic of Tube-in-Tube device. A) 
Configuration with liquid flow within inner AF-2400 tubing, and 
gas flow in outer jacket (as used in this work). B) Alternative 
configuration with gas in inner AF-2400 tubing and liquid flow 
in outer jacket.  
 
As part of a program investigating the use of gas-liquid flow 
technologies as a replacement for traditional batch hydrogenation 
and hydrogenolysis processes, we were interested in their 
application to the synthesis of 1.  
 
 
   A key consideration when using gases in continuous flow is the 
nature of the contact between the gas and liquid phases. In 
systems where biphasic flow streams are generated, governing 
the morphology of the flow regime is not always 
straightforward.10 A number of different approaches to gas-liquid 
contacting in flow have been developed, many of which provide 
enhanced mass transfer of gas between the two phases, often by 
maximising the interfacial surface area.11 For hydrogenation 
reactions, the commercially available H-Cube system has also 
seen growing popularity among synthetic chemists.12  
   We have previously demonstrated that flow reactors based on 
gas-permeable membranes, such as Teflon AF-2400,13 which 
combines very high levels of gas permeability with excellent 
chemical resistance properties, facilitate the reliable and scale-
invariant generation of homogeneous flow streams of reactive 
gasses in solution.14 These devices avoid many of the 
complications associated with heterogeneous biphasic flow 
regimes which result from 'mechanical mixing' of gas and liquid 
flow streams. The relationship between gas concentration and 
operational variables, such as residence time, gas pressure, and 
tubing dimension, is straightforward and can be reliably 
modelled using standard mathematical analyses.15 When high 
pressures of gas are required to achieve sufficient solution 
concentrations, the 'tube-in-tube' configuration (Figure 2) is an 
efficient arrangement which keeps the volume of pressurised gas 
to a minimum. A simple and inexpensive 'tube-in-tube' device 
can easily be constructed using just two standard T-piece 
junctions (e.g. Swagelok), as shown in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Photograph of the Tube-in-Tube device used in this 
work. The plastic ruler the Swagelok T-pieces are cable-tied to is 
used only for attachment and to provide a scale. The left-hand T-
piece was connected to the hydrogen cylinder via a standard 2-
stage poppet regulator. The right-hand T-piece was connected to 
a stopcock that was normally closed during operation, so that the 
jacket of gas remained 'static' (the only flow of gas being through 
the AF-2400 tubing into the liquid flow stream).   
 
    Whilst commercial gas-liquid flow devices tend to be well 
engineered, and can perform admirably in a wide range of 
hydrogenation applications, their proprietary nature generally 
precludes full disclosure of their internal design and workings 
(including materials). This encourages a ‘black box’ approach 
which may inhibit further modification and/or development of 
the systems by the user. The simple and fully disclosed nature of 
these Teflon AF-2400 based devices is perhaps one of the 
reasons (in addition to their low cost) for their rapidly growing 
popularity.  
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    We, and others, have successfully demonstrated the use of 
Teflon AF-2400 based reactors with a number of reactive gasses 
including ozone,16 oxygen,17 ammonia,18 methylamine,19 carbon 
dioxide,15b, 20 carbon monoxide,19, 21 ethylene,22 diazomethane23, 
formaldehyde,24 and fluoroform.25 Importantly, in the context of 
the current work, they have been used with hydrogen gas,22c, 26 on 
its own or as a mixture with carbon monoxide (syngas).22b, 27  
 
2. Results and Discussion  
 
2.1. Reduction of Simple Nitroarenes.  
 
 
 
 
 
 
 
Figure 4. Schematic of the flow setup.  
   Prior to attempting a synthesis of 1 using gas-liquid flow 
hydrogenation, we first wanted to establish that the system was 
capable of effecting the hydrogenation of simple nitroarene 
compounds 5a-i in continuous flow28 using the general setup 
shown in Figure 4. The starting material was loaded into a flow 
stream of solvent using an injection loop. The flow stream 
becomes enriched with hydrogen gas by passing through a 
relatively short 10 cm Tube-in-Tube device (this single Tube-in-
Tube device was used for all the work described in this paper). 
We have previously found that saturation is rapid using hydrogen 
gas with Tube-in-Tube reactors. Upon exiting the Tube-in-Tube 
stage, the flow stream passes through a glass omnifit cartridge 
containing Pd-C (5%). We found that back-pressure due to 
compression/blocking of the catalyst powder could be avoided by 
mixing it with celite (1:1 wt:wt) and packing it into the cartridge 
with plugs of celite and sand at each end (see Figure 4). Using 
the powdered supported catalyst by itself led to a significant and 
variable build up of back-pressure. During a brief initial 
screening (of solvent, flow rates etc), we used a small cartridge 
(11.1 mm OD, 6.6 mm ID) containing 370 mg of 5% palladium 
on carbon (which was used repeatedly). It was found that 15 mg 
of nitroanisole 5a, (injected as a 0.027 M EtOH solution in a 3.6 
mL loop) could be cleanly converted to the corresponding aniline 
6a with quantitative conversion and in high yield using ethanol as 
solvent with a flow rate of 0.5 ml min-1 and a hydrogen pressure 
of 16 bar. No premature outgassing (formation of hydrogen 
bubbles) upstream of the 13 bar back-pressure regulator was 
observed under these conditions. A noticeable drop in outgassing 
downstream of the back pressure regulator was observed about 
15 minutes after injection, indicating that hydrogen was being 
used up. This continued until about 20 minutes after injection, at 
which point the outgassing reached its original level, indicating 
that the rate of hydrogen consumption had significantly 
diminished. It should be pointed out that the system was allowed 
to equilibrate for 30 minutes under H2 pressure prior to the 
injection of the substrate solution, after which time the rate of 
hydrogen outgassing downstream of the back pressure regulator 
reached a steady state. The product stream was collected at the 
outlet for 40 min. The reaction was then increased in scale, using 
a larger cartridge (20.0 mm OD, 15.0 mm ID) containing 1.0 g of 
palladium on carbon, again with a hydrogen pressure of 16 bar. A 
0.152 M solution of 5a (84 mg in 3.6 mL) was injected into an 
EtOH flow stream at 0.5 mL min-1. The outlet solution was 
collected for 120 minutes and the product was isolated by 
removing the solvent under reduced pressure to afford a mixture 
of the desired aniline 6a and the starting material 5a in a ratio of 
approximately 3:1. When the concentration of starting material 
was lowered to 0.076 M (42 mg in 3.6 mL EtOH), under the 
same conditions, the conversion was complete and the desired 
product 6a was isolated in a very high yield of 95 %. Likewise, 
when the hydrogenation of tert-butyl nitrophenylpropanoate 5b 
was attempted at a concentration of 0.152 M, the product was 
isolated alongside unreacted starting material (6b:5b = 2:1) but 
when the reaction was carried out at 0.076 M, complete 
conversion to 6b was observed. Using a concentration of 0.076 
M, a series of nitroarene compounds 5a-i was cleanly converted 
to the corresponding anilines 6a-i which were isolated in very 
high yields. (Scheme 2). 1H and 13C NMR alongside MS analysis 
confirmed the desired nitro to aniline conversions had occurred 
and that nitroso products were not formed. Having thus 
established that we could perform simple nitro reduction using 
our gas-liquid flow hydrogenation setup, we next attempted the 
proposed nitro-reduction/cyclisation/imine-reduction domino 
process to access 1 from 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Results of continuous flow nitroarene hydrogenations. 
Conversions were determined by 1H NMR. Yields refer to 
isolated yields based on mass recovery. The starting material for 
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6i was 2-fluoro-5-nitro-aniline. The same cartridge of Pd-C 
catalyst was used for all substrates.  
 
2.2. Pyrrolobenzazepine synthesis using gas-liquid flow 
hydrogenation.  
 
 In our initial investigations for the continuous-flow 
conversion of 4 into 1, we reverted to using the smaller cartridge 
of palladium catalyst (11.1 mm OD, 6.6 mm ID, 370 mg of 5% 
Pd-C). Again using EtOH as a solvent, nitro-aldehyde 4 (easily 
obtained from alkylation of 2-nitrobenzyl bromide with pyrrole-
2-carbaldehyde5) at a concentration of 8.7 mM (7.2 mg in 3.6 
mL) was exposed to analogous flow conditions (0.5 mL min-1, 16 
bar H2). The outlet was collected for 45 minutes. Analysis of the 
isolated product material by 1H NMR suggested that the majority 
of the starting material, approximately 65%, had not been 
converted to the desired product 1, but to another compound with 
quite similar spectral features. Data reported in the literature for 1 
suggested that this was, in fact, the minor component, formed in 
35% yield. We were thus interested in firmly establishing the 
identity of the two products. 1H NMR analysis indicated that, in 
both products, two CH2X (X = heteroatom) environments were 
present. This suggested that aldehyde reduction had occurred and 
that the amino-alcohol structure 7 was a possibility for the major 
product. Consistent with this, we found, after chromatographic 
separation, that the major product also had a significantly lower 
Rf value than the minor product. It occurred to us that the 
formation of 7 might result from hydrogenation of the aldehyde 
prior to the nitro group. 
 
 
 
 
 
 
Scheme 3 Reductive cyclisation of pyrrolocarbaldehyde 4 to 1 and 
formation of the minor reaction by-product 7. 
 
We separately synthesised 1 and 7 from 4 in batch. To access 
1 we used the same solvent and catalyst, but at atmospheric 
(balloon) pressure of H2 and isolated the desired product 1 in 
60% yield after chromatography. To obtain 4 we used an 
alternative two-step proces. (68% overall yield, Scheme 4). 
NaBH4 treatment of 4 proceeded smoothly to deliver novel nitro 
alcohol 8 in 90% yield. Using mildly basic conditions and H2 
generated in situ from sodium hypophosphite (NaH2PO2), Pd/C 
catalysed reduction of 8 delivered 7 smoothly in 75% isolated 
yield (with no evidence of any cyclisation to 1). Attempts to 
access 7 using acidic nitro-reducing conditions (Fe/AcOH) were 
unsuccessful, leading to extensive material degradation.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Batch synthesis of anilino-alcohol 7 and 
pyrrolobenzazepine 1; i) Pd/C, H2, EtOH, 60% ii) NaBH4, THF, 75% 
iii) Pd/C, K2CO3, H2O, THF, 90%. 
 
We compared our NMR data for 7 with the initial gas-liquid 
flow results as well as with the spectra of pure 1 (selected 1H 
region shown in Figure 5, bottom, blue line). The product of the 
hydrogenation of 8 and the major product from the flow 
hydrogenation had identical 1H and 13C NMR spectra as well as 
identical Rf values. This corroborated our conclusion that flow 
hydrogenolysis conditions had converted 65% of 4 to 7 and 35% 
to 1. The structures of products 1 and 7 from the batch reactions 
were further confirmed by Mass Spectrometry and single-crystal 
X-ray diffraction (see Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 400 MHz 1H NMR overlays of initial attempted synthesis  
of 1 using gas-liquid flow hydrogenolysis (bottom, blue line) and 
using traditional batch conditions1a,b, 4 (top). The spectra of 7 made in 
batch via hydrogenation of nitro-alcohol 8 is overlaid on the bottom 
spectrum as a green line.  
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Figure 6. X-ray structures of 1 (top) and 7 (bottom, thermal 
ellipoids shown at 50%). 
It was found that, if the crude 35:65 mixture of 1 and 7 
obtained in flow was re-injected into the continuous flow system, 
then the product that emerged from this second pass (which was 
isolated with quantitative mass recovery) contained 
predominantly 7 (now in a 1:12 ratio of 1:7). This suggested the 
possibility that 1 might be an intermediate in the formation of 7. 
To test this hypothesis, we separately passed purified samples of 
1 and 7 through the flow system again and found that they were 
recovered, unaltered, in essentially quantitative yield, which 
negates the suggestion that 7 is formed from 1. As the 36:65 ratio 
mixture of 1 and 7 that was recycled was crude, we cannot rule 
out the possibility that it contained residual palladium that may 
have catalysed changes in the time between the two runs 
(including exposure to NMR solvents etc.). The fact that the 
relative proportions of 1 and 7 seem to be sensitive to the 
concentration of 4 at a given hydrogen pressure and flow rate 
(more 7 being formed at a lower substrate concentration) 
suggests that the aldehyde in 1 might be undergoing 
hydrogenative reduction to the alcohol when the hydrogen 
concentration is higher. If aldehyde hydrogenation occurs either 
before the nitro group is reduced, or before the formation of the 
imine intermediate (which is perhaps more likely as reduction of 
the nitro group might also be expected to proceed more rapidly at 
higher hydrogen concentration), this would explain the formation 
of 7. Whilst transition-metal catalysed hydrogenations of pyrrolic 
aldehydes are known,29 literature precedent suggests that the nitro 
group should be reduced more quickly under these conditions.30  
    Consistent with this, when 4 was injected under the same 
conditions, but with the addition of 20 equivalents of pyridine 
(which is a known poison/modifier of palladium catalytic 
activity31) then 1 was obtained in a 2.7:1 ratio with 7. Also, when 
36 mg of nitro-alcohol 8 (in 18 mL EtOH) was subjected to the 
flow hydrogenation conditions (using the larger 1g Pd-C 
cartridge, H2 at 16 bar, 0.5 mL min-1), the amino-alcohol 7 was 
the sole product, isolated in 97% yield, strongly suggesting that 7 
is not a precursor to 1 
Having fully established the identity of the two products from 
the flow hydrogenation reaction, we were keen to optimise 
conditions to favour production of the desired material 1. Whilst 
the addition of pyridine was observed to have a positive influence 
in this regard, we noticed that its effect on the smaller catalyst 
cartridge was not quickly reversed and flushing with copious 
fresh solvent was required to 'regenerate' the original catalytic 
activity. Wanting to avoid complications arising from cumulative 
(and perhaps variable) poisoning effects over time, we 
investigated whether the same outcome could be obtained by 
varying simple parameters such as concentration. Pleasingly, 
when 4 was injected in a higher concentration of 0.0217 M (90 
mg in 18 mL EtOH), with a flow rate of 0.5 mL min-1 and an H2 
pressure of 16 bar, using the larger catalyst cartridge (1.0 g of Pd-
C) the desired compound 1 was obtained in a yield of 95%, and 
in the absence of the ring-opened by-product 7.  
For larger scale runs, the injection loop became unsuitable and 
the substrate solution was introduced directly through the pump 
inlet (Figure 7). When the scale was increased to 500 mg (at the 
same concentration: 21.7 mM, 500 mg in 100 mL EtOH) then we 
found that significant amounts of unreacted starting material 4 
were obtained, alongside the product 1 and other components 
(not including 7), Table 1, entry 1. This reduction in conversion 
at a higher scale might be explained by the palladium acting as a 
‘reservoir’ of hydrogen. During the equilibration prior to the start 
of the run, it may take up and store a quantity of hydrogen and, 
after equilibration is reached, outgassing of hydrogen is then 
observed downstream of the back pressure regulator. During the 
run, once the starting material is introduced, this stored hydrogen 
may (for a while) allow higher conversion than would be possible 
solely from the hydrogen present in solution. Clearly, any stored 
hydrogen will be consumed and, during longer runs (i.e. larger 
scale reactions) may become completely depleted, leading to 
lower conversions.  
 
 
 
 
 
 
Figure 7. For the larger (500 mg) scale experiments, the starting 
material 4 was added directly through the pump inlet.  
Using a lower concentration of subsrate (14.5 mM, 500 mg in 
150 mL) and a higher pressure of hydrogen (25 bar, with the 
back pressure regulator adjusted to 20 bar), the loss of starting 
material was complete but now the product 1 was accompanied 
by a significant amount of amino alcohol 7 (1:7 = 1:0.87, Table 
1, entry 2). Lowering the pressure to 20 bar (at this reduced 
concentration) reduced the quantity of 7 obtained (1:7 = 1:0.40, 
Table 1, entry 3). Pleasingly, by using this 20 bar pressure with 
the original concentration (21.7 mM), we were able to obtain a 
product which contained minimal quantities of 7 (1:7 = 1:0.05) 
and, after column chromatography, the isolated product 1 was 
obtained in an 81% yield (356 mg). 
 
Entry H2 (bar) Conc.(mM) 
S.M. 
consumed? 1:7 Yld (1) 
1 16 21.7 N - - 
2 25 14.5 Y 1:0.87 - 
3 20 14.5 Y 1:0.40 - 
4 20 21.7 Y 1:0.05 81% 
 
Table 1. Results for the 500 mg scale hydrogenations of 1. Yld 
refers to the isolated yield of 1 after column chromatography on 
silica gel.  
 
3. Conclusion 
In conclusion, we have developed a simple and effective 
continuous-flow heterogeneous hydrogenation protocol for 
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nitroarenes based around an inexpensive Teflon AF-2400 tube-
in-tube reactor. This was used to effect the formation of a series 
of substituted anilines in high yields and high purities. With 
nitro-aldehyde 4, the flow conditions could be tuned to 
preferentially obtain either the desired 
pyrrolobenzo[1,4]diazapene compound 1 or the amino-alcohol 
by-product 7. Despite the fact that 7 was not the desired 
compound in this particular case, this nevertheless demonstrates 
that the flow conditions used can provide controlled access to 
alternative products. There appears to be a relationship between 
the relative amounts/concentrations of the starting material/H2 
and the product selectivity. We are currently performing 
investigations aimed at establishing the mechanistic manifold by 
which 1 and 7 are formed, including a comparison between flow 
and batch modes across a range of pressures (it should be pointed 
out that the batch hydrogenation in this work was only carried 
out at atmospheric pressure). We are also investigating whether 
the palladium is acting as a hydrogen reservoir (and the effect 
this has on the reactivity), as well as the extent of any palladium 
leaching, and will report our findings in due course.  
4. Experimental Section 
1H NMR spectra were recorded on a Bruker Avance 300 
(300.1 MHz) instrument or a Bruker Avance 400 (399.9 MHz) 
instrument using deuterochloroform (or other indicated solvent) 
as reference. The chemical shift data for each signal are given as 
δ in units of parts per million (ppm) relative to tetramethylsilane 
(TMS) where δ (TMS) = 0.00 ppm. The multiplicity of each 
signal is indicated by: s (singlet); brs (broad singlet); d (doublet); 
t (triplet); dd (doublet of doublets); ddd (doublet of doublet of 
doublets); dddd (doublet of doublet of doublet of doublets); ddt 
(doublet of doublet of triplets); sp (septet) or m (multiplet). The 
number of protons (n) for a given resonance is indicated by nH. 
Coupling constants (J) are quoted in Hz and are recorded to the 
nearest 0.1 Hz. 13C NMR spectra were recorded on a Bruker 
Avance 300 (75.5 MHz) instrument using the PENDANT 
sequence and internal deuterium lock. The chemical shift data for 
each signal are given as δ in units of ppm relative to TMS where 
δ (TMS) = 0.00 ppm. Where appropriate, coupling constants (J) 
are quoted in Hz and are recorded to the nearest 0.1 Hz. Melting 
points were determined using Gallenkamp MF-370 or 
Electrothermal 9100 melting point apparatuses and are 
uncorrected. Analytical thin layer chromatography ( LC) was 
carried out on pre-coated 0.25 mm ICN Biomedicals GmbH 60 
F254 silica gel plates. Visualisation was by absorption of UV 
light, or thermal development after dipping in 5 % H2SO4 in 
MeOH. Manual Column chromatography was carried out on 
silica gel (Apollo Scientific Ltd 40- 63 micron) under a positive 
pressure of compressed air. Automatic Column Flash 
chromatography was carried out on silica gel (Reveleris® X2 
system) under a positive pressure of compressed N2. Dry CH2Cl2 
and DMF was acquired from an Innovative Technology solvent 
purification system. Anhydrous MeOH was dried over 4 Å 
molecular sieves. Chemicals were purchased from Acros UK, 
Aldrich UK, Avocado UK, Fisher UK or Fluka UK. All solvents 
and reagents were purified and dried where necessary, by 
standard techniques. Where appropriate and if not stated 
otherwise, all non-aqueous reactions were performed under an 
inert atmosphere of nitrogen, using a vacuum manifold with 
nitrogen passed through 4 Å molecular sieves and self-indicating 
silica gel. In vacuo refers to the use of a rotary evaporator 
attached to a diaphragm pump. Brine refers to a saturated 
aqueous solution of sodium chloride. Hexane refers to n-hexane 
and petroleum ether to the fraction boiling between 40-60 °C. 
The heterocyclic ring numbering for NMR assignments of 7 and 
8 is shown in the supplementary material. 
Flow apparatus: A Knauer Azura P-4.1S HPLC pumping unit 
was used to pump the solvent through the system. Aside from the 
Tube-in-Tube device, the general liquid flow line consisted of 
FEP tubing (1/16’’ x 1.0 mm ID, VICI-jour) and the tubing 
interconnects were of the flat seated Omnifit/Diba type (1/4-28-
UNF thread). The backpressure regulator was an Upchurch/IDEX 
type (Kinesis UK) and was manually adjusted to provide the 
desired back pressure of 13 bar (gauge), as measured using the 
pressure meter of the Knauer Azura pump. The injection loop 
was constructed using four Omnifit/Diba 3-way valves (two 
valves to open/close the loop itself for filling, two valves to 
connect/disconnect the loop to the flow stream). The hydrogen 
pressure in the Tube-in-Tube device was regulated at the cylinder 
outlet using a Gas-Arc Techmaster GA600 multi-stage regulator. 
As shown in Figure 3, the side-port of one of the Swagelok T-
pieces of the Tube-in-Tube device was connected to the regulator 
outlet, and the side-port of the other T-piece was connected to a 
Swagelok stopcock (which was closed during normal operation 
and only used for maintenance/start-up/shutdown etc). With this 
arrangement, the hydrogen gas could only exit the Tube-in-Tube 
device during normal operation by passing into the solvent flow 
stream.  
4.1 Pyrrolobenzodiazepine 1 
Batch: To a stirred solution of 1-[(2-
nitrophenyl)methyl]pyrrole-2-carbaldehyde 4 (300 mg, 1.30 
mmol, 1.0 equiv.) in EtOH (4 mL), was added 5% Pd-C (5.5 mg, 
0.002 equiv.) and the reaction mixture left stirring overnight 
under a H2 atmosphere (balloon). Upon completion, as indicated 
by TLC (1/2, ethyl acetate/hexane), the mixture was filtered 
through Celite™ and the solution concentrated in vacuo. The 
crude product was purified by Reveleris® automated silica gel 
flash column chromatography (liquid injection onto column), 
eluting with ethyl acetate/hexane (0/100, 40/60, 60/40 and 
100/0), furnishing 1 (160 mg, 0.79 mmol, 60%) as a brown solid. 
Rf 0.61 (1/2, ethyl acetate/hexane); 
Flow (500 mg run): The system (see Figure 6), incorporating 
the 1g Pd-C cartridge (20.0 mm OD, 15.0 mm ID), was primed 
by pumping through ethanol at a rate of 0.5 mL min-1. No 
injection loop was used. A 20 bar back pressure regulator was 
used. To avoid an overpressure of the system in the event of 
blockage, the upper pressure cut-off limit on the Knauer pump 
was set to 25 bar. The tube-in-tube device was subjected to 20 
bar of hydrogen pressure using a 2-stage regulator on the 
cylinder. Priming continued for 30 minutes before starting the 
run (out-gassing of hydrogen downstream of the back-pressure 
regulator could be observed after about 20 minutes). The starting 
nitro-aldehyde 4 (500 mg, 2.17 mmol) was dissolved in EtOH 
(100 mL solution). To introduce the starting material solution, 
the pump was momentarily stopped and the inlet was switched 
from the EtOH reservoir to the starting material solution. The 
pump was then immediately restarted. The level of the inlet 
solution was monitored and at the moment when it had all been 
taken in (but before any air could be drawn in to the pump inlet 
line), the pump was momentarily stopped and the inlet line 
switched back to the EtOH reservoir. The pump was then 
immediately restarted. The output from the system was collected 
for 450 minutes. Solvent was removed under reduced pressure 
(using a rotary evaporator followed by a 2-stage rotary vane 
pump) to afford an off-white solid (450 mg crude). The material 
was purified using column chromatography on silica gel (Merck 
9385 grade) eluting with a gradient from petroleum ether to ethyl 
acetate, to afford 1 as a white solid (356 mg, 81%); 
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1H NMR (300 MHz; CDCl3) δ 7.08-7.00 (m, 2H, H4, H2), 
6.71 (t, J = 2.1 Hz, 1H, H5), 6.65 (td, J = 7.4, 1.1 Hz, 1H, H3), 
6.52 (dd, J = 8.0, 1.0 Hz, 1H, H1), 6.08-6.05 (m, 2H, H6, H7), 
5.21 (s, 2H, CH2N), 4.49 (s, 2H, CH2O), 3.71 (brs, 1H, NH); 13C 
NMR (75 MHz; CDCl3) δ 146.5, 131.0, 129.9, 128.8, 120.6, 
120.0, 117.79, 117.65, 106.2, 105.6, 51.6, 40.7; MS ESI+ m/z 
185 ([M+Na]+, 100 %); HRMS ESI+ m/z Found: 185.1071 for 
C12H13N2 [(M+H)+] requires 185.1073; Data matched those 
previously reported1b; CCDC No: 1584964. 
General Procedure for Flow hydrogenation of Nitro Arenes 
(Scheme 2): 
Before each run, the system (see Figure 4) was allowed to 
equilibrate by pumping solvent through for 30 minutes with the 
Tube-in-Tube device at 16 bar of hydrogen. An omnifit cartridge 
(20.0 mm OD, 15.0 mm ID) containing 1g of Pd-C catalyst was 
used. To avoid an overpressure of the system in the event of 
blockage, the upper pressure cut-off limit on the Knauer pump 
was set to 25 bar. With the injection loop disconnected from the 
flow line, the loop was opened and filled manually (using a 
syringe) with 3.6 mL of a 0.076 M solution of starting material in 
ethanol (excess starting material solution exiting the loop was 
recovered for reuse). The injection loop was then closed off and 
switched into the flow stream. The outlet from the system 
(downstream of the back-pressure regulator) was collected for 
120 min. The solvent was removed under reduced pressure (using 
a rotary evaporator followed by a 2-stage rotary vane pump) to 
afford the product.  
4.2. 4-amino methoxybenzene 6a 
32.0 mg from 41.9 mg 5a (95%). 
1H NMR (400 MHz, CDCl3) δ 6.78 (d, J = 8.3 Hz, 2H), 6.69 (d, 
J = 8.3 Hz, 2H), 3.78 (s, 3H), 3.39 (br.s, 2H); 13C NMR (101 
MHz, CDCl3) δ 152.9, 139.9, 116.4, 114.9, 55.8. The data are 
consistent with values reported in the literature.32 
 
4.3. 1 tert-Butyl 3-(4-aminophenyl)propionate 6b 
59.9 mg from 68.8 mg 5b (99%).  
1H NMR (400 MHz, CDCl3) δ 6.98 (d, J = 7.7 Hz, 2H), 6.61 (d, J 
= 7.6 Hz, 2H), 3.57 (br.s, 2H), 2.79 (t, J = 7.8 Hz, 2H), 2.47 (t, J 
= 7.8 Hz, 2H), 1.42 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
172.5, 144.5, 130.9, 129.1, 115.2, 80.2, 37.5, 30.4, 28.1; HRMS 
(ESI-TOF, m/z): calculated for C18H20NO2 ([M+ H]+): 222.1489, 
found: 222.1484. The data are consistent with values reported in 
the literature.33 
 
4.4. Methyl-3-methyl-4-nitro benzoate 6c 
43.4 mg from 53.4 mg 5c (96%). 
1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 7.7 Hz, 1H), 7.05 
(app.t, J = 7.8 Hz, 1H), 6.82 (d, J = 7.9 Hz, 1H), 3.88 (s, 3H), 
3.73 (br.s, 2H), 2.34 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
169.1, 145.5, 131.6, 126.1, 122.9, 120.4, 118.2, 51.9, 13.8; 
HRMS (ESI-TOF, m/z): calculated for C9H11NO2 ([M+ H]+): 
166.0863, found: 166.0857. The data are consistent with values 
reported in the literature.34 
 
4.5. 4-Amino-3-fluoro-benzoic acid 6d 
41.6 mg from 50.6 mg 5d (98%).  
1H NMR (400 MHz, CD3CN) δ 7.63 (d, J = 8.3 Hz, 1H), 7.59 (s, 
1H), 6.84 (t, J = 8.4 Hz, 1H); 13C NMR (101 MHz, CD3CN) δ 
167.1, 151.7, 149.4, 141.5, 127.7, 116.9, 115.6; HRMS (ESI-
TOF, m/z): calculated for C6H7FNO2 ([M+ H]+): 156.0455, 
found: 156.0453. 
 
4.6. 5-Amino-2-methyl-benzoic acid 6e 
39.3 mg from 49.6 mg 5e (95%).  
1H NMR (400 MHz, CD3CN) δ 7.20 (s, 1H), 7.03 (d, J = 8.0 
Hz, 1H), 6.76 (d, J = 7.7 Hz, 1H), 4.26 (br.s, 2H,), 2.42 (s, 3H); 
13C NMR (101 MHz, CD3CN) δ 169.2, 146.4, 132.8, 130.7, 
128.5, 118.8, 116.7, 20.3; HRMS (ESI-TOF, m/z): calculated 
for C8H10NO2 ([M+ H]+): 152.0706, found: 152.0701. The data 
are consistent with values reported in the literature.35 
 
4.7. 3-Amino-4-fluoro-benzoic acid 6f 
40.3 mg from 50.6 mg 5f (95%).  
1H NMR (400 MHz, CD3CN) δ 7.48 (d, J = 8.8 Hz, 1H), 7.37 – 
7.28 (m, 1H), 7.07 (t, J = 9.8 Hz, 1H); 13C NMR (101 MHz, 
CD3CN) δ 167.3, 155.9, 153.5, 136.5, 127.4, 120.1, 118.3, 115.7; 
HRMS (ESI-TOF, m/z): calculated for C7H7FNO2 ([M+ H]+): 
156.0455, found: 156.0449. The data are consistent with values 
reported in the literature.36 
 
4.8. 4-Amino-2-methyl-benzoic acid 6g 
40.5 mg from 49.5 mg 5g (98%).  
1H NMR (400 MHz, CD3CN) δ 7.79 (d, J = 8.3 Hz, 1H), 6.50 (d, 
J = 6.8 Hz, 2H); 13C NMR (101 MHz, CD3CN) δ 169.3, 152.7, 
143.8, 134.1, 117.1, 116.9, 111.5, 22.2; HRMS (ESI-TOF, m/z): 
calculated for C8H10NO2 ([M+ H]+): 152.0706, found: 152.0700.  
 
4.9. 3-Amino-4-fluoro-benzonitrile 6h 
36.1 mg from 45.4 mg 5h (97%).  
1H NMR (400 MHz, CDCl3) δ 7.09 – 6.98 (m, 3H), 3.98 (br.s, 
2H); 13C NMR (101 MHz, CDCl3) δ154.9, 152.5, 135.9, 122.9, 
119.7, 118.5, 116.3, 108.6. 
 
4.10 2,4-Diamino-1-fluorobenzene 6i 
32.8 mg from 42.7 mg 5i (95%).  
1H NMR (400 MHz; CDCl3) δ  6.80 (t, J = 9.7 Hz, 1H), 6.14 (dd, 
J = 7.6, 2.1 Hz, 1H), 6.03 (d, J = 8.5 Hz, 1H), 3.64 (s, 2H), 3.51 
(s, 2H); 13C NMR (101 MHz; CDCl3) δ 115.7, 115.5, 105.1, 
105.0, 103.7, 103.7; HRMS (ESI-TOF, m/z): calculated for 
C6H8FN2 ([M+ H]+ ): 127.0666, found: 127.0667. The data are 
consistent with values reported in the literature.37 
 
4.11. 1-[(2-aminophenyl)methyl]pyrrole-2-carbinol 7 
Batch: a slurry consisting of 8 (200 mg, 0.86 mmol, 1 equiv.), 
K2CO3 (80 mg, 0.60 mmol, 0.7 equiv.), 5% Pd-C (4 mg, 0.002 
equiv.) in H2O (1.0 mL) and THF (1.5 mL) was heated to 60 °C. 
To this vigorously stirred mixture was added dropwise a solution 
of NaH2PO2 (350 mg, 3.27 mmol, 3.8 equiv.) in H2O (1 mL). The 
reaction was refluxed for 3 h, cooled to room temperature, and 
toluene (5 mL) was added. The mixture was then filtered through 
Celite™, the layers separated, and the aqueous extracted with 
toluene (2 x 10 mL). The combined organic layers were washed 
with H2O (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude product was crystallised from hexane/diethyl 
ether (1/1) to yield 7 (90 mg, 0.49 mmol, 65%) as a brown 
powder; 
Flow: The system (see Figure 4), incorporating the 1g Pd-C 
cartridge (20.0 mm OD, 15.0 mm ID), was primed by pumping 
through ethanol at a rate of 0.5 mL min-1. To avoid an 
overpressure of the system in the event of blockage, the upper 
pressure cut-off limit on the Knauer pump was set to 25 bar. The 
tube-in-tube device was subjected to 16 bar of hydrogen pressure 
using a 2-stage regulator on the cylinder. Priming continued for 
30 minutes before starting the run (out-gassing of hydrogen 
downstream of the back-pressure regulator could be observed 
after about 20 minutes). The starting nitro-alcohol 8 (36.0 mg, 
0.155 mmol) was dissolved in EtOH (18 mL solution). This 
solution was loaded into an 18 mL injection loop using a syringe. 
The injection loop was switched into the flow stream and the 
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output from the system was collected for 180 min. Solvent was 
removed under reduced pressure (using a rotary evaporator 
followed by a 2-stage rotary vane upmp) to afford an off-white 
solid (27.8  mg, 97%); 
Rf 0.17 (1/2, ethyl acetate/hexane); mp 113-115 oC; 1H NMR 
(400 MHz; CDCl3) δ 7.18 (t, J = 7.7 Hz, 1H, H2), 7.01 (d, J = 7.3 
Hz, 1H, H4), 6.80 (t, J = 7.1 Hz, 1H, H3), 6.71 (d, J = 8.0 Hz, 1H, 
H1), 6.64 (t, J = 2.2 Hz, 1H, H5), 6.20 (dd, J = 3.3, 1.7 Hz, 1H, 
H6), 6.13 (t, J = 3.1 Hz, 1H, H7), 5.10 (s, 2H, CH2N), 4.66 (s, 2H, 
CH2O); 13C NMR (100 MHz; CDCl3) δ 144.9, 131.6, 129.8, 
129.2, 122.4, 121.5, 118.7, 116.3, 109.5, 107.6, 56.6, 47.9; MS 
ESI+ m/z 225 ([M+Na]+, 100%); HRMS ESI+ m/z Found: 
225.1013 for C12H14N2ONa [(M+Na)+] requires 225.0998; CCDC 
No: 1816148. 
4.12. 1-[(2-nitrophenyl)methyl]pyrrole-2-carbinol 8 
To a stirred solution of 1-[(2-nitrophenyl)methyl]pyrrole-2-
carbaldehyde1 (200 mg, 0.87 mmol, 1 equiv.) in dry THF (8 mL) 
at 0 °C was added NaBH4 (60 mg, 1.6 mmol, 1.9 equiv.) and 
stirring was continued for 48 h at room temperature. The reaction 
mixture was acidified with 1 M HCl to pH 5 and the solvent 
removed in vacuo. The crude oil was reconstituted between H2O 
(25 mL) and CH2Cl2 (25 mL) and the aqueous phase extracted 
with CH2Cl2 (2 x 25 mL). The combined organic phases were 
washed with saturated aqueous sodium chloride (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by 
Reveleris® automated silica gel flash column chromatography 
(liquid injection onto column), eluting with ethyl acetate/hexane 
(0/100, 40/60, 60/40 and 100/0) afforded 8 (180 mg, 0.77 mmol, 
93%) as a brown solid. Rf = 0.38 (1/2, ethyl acetate/hexane); m.p. 
98-100 oC; 1H NMR (300 MHz; CDCl3) δ 8.15 (dd, J = 8.1, 1.4 
Hz, 1H, H1), 7.53 (td, J = 7.6, 1.4 Hz, 1H, H3), 7.47-7.41 (m, 1H, 
H2), 6.70 (dd, J = 2.7, 1.8 Hz, 1H, H5), 6.46 (dd, J = 7.7, 1.2 Hz, 
1H, H4), 6.23-6.18 (m, 2H, H6, H7), 5.61 (s, 2H, CH2N), 4.44 (s, 
2H, CH2OH), 1.84 (br.s., 1H, OH); 13C NMR (75 MHz; CDCl3) 
δ 146.7, 135.5, 134.4, 132.1, 128.2, 128.0, 125.0, 123.5, 109.9, 
108.2, 56.5, 48.3; MS ESI- m/z 231 ([M-H]-, 100%); HRMS 
ESI- m/z Found: 231.0776 for C12H11N2O3 [(M-H)-], requires 
231.0775. 
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